|Podcasts|March 3, 2011
Merck's Biosimilars Business, from Parexel's Perspective
Advertisement
Merck's Biosimilars Business, From Parexel's Perspective
Josef von Rickenbach, Chairman and CEO of Parexel, discusses why Parexel won the Merck biosimilars’ business, differences in recruitment for biosimilars, and trends for 2011, including the 20-year promise of technology now being realized.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
2
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
3
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
4
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
5